ArticleJTCVS open2026
Outcomes after lung retransplantation for restrictive allograft syndrome have not improved over 2 decades.
Article in JTCVS open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Objective: In 2015, restrictive allograft syndrome (RAS) was first definitively associated with poorer outcomes after lung retransplantation compared with bronchiolitis obliterans syndrome (BOS). This study aimed to evaluate how strategies and outcomes of lung retransplantation for RAS have evolved over time. Methods: The United Network for Organ Sharing database was queried to identify adult lung retransplants for RAS between 2005 and 2025. Primary transplants, multiorgan transplants, and retransplants with unknown indications were excluded. Patients were stratified into Era 1 (2005-2015) and Era 2 (2016-2025). The primary outcome was 5-year survival. Results: A total of 293 patients were included, with 141 (48%) in Era 1 and 152 (52%) in Era 2. The proportion of retransplants for restrictive disease was similar across eras (19% vs 22%, Conclusions: Since 2015, lung retransplantation for RAS has increasingly favored bilateral procedures, accompanied by greater perioperative support. Despite these changes, long-term survival remains poor, underscoring the need for improved candidate selection and strategies to prevent recurrent chronic allograft injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.